<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this study we describe the morphologic and immunohistochemical evaluation of bone marrow biopsies from 14 patients with therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We employed CD34, anti-HLA-Dr, anti-elastase, CD68, anti-glycophorin, CD61 monoclonal antibodies immunostaining, and enzyme histochemistry for chloroacetate esterase </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, we used PC10, a MAb raised against the proliferating cell nuclear antigen, to study the proliferative capacity of these marrows </plain></SENT>
<SENT sid="3" pm="."><plain>Our data suggest that diagnosis of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (versus <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>), the abnormal localization of immature precursors, marrow <z:mp ids='MP_0003045'>fibrosis</z:mp>, and augmented CD34 expression in the bone marrow biopsy are ominous prognostic factors at a statistically significant level (p &lt; 0.0005) </plain></SENT>
<SENT sid="4" pm="."><plain>A combined morpho-immunohistochemical analysis of bone marrow biopsy correctly classifies t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases according to the biologic and clinical <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> </plain></SENT>
</text></document>